Advances in Immunotherapy through Oncolytic Viruses
Transgene, a biotechnology company based in France, has successfully given a new immunotherapeutic drug to a first person in a Phase 1/2a clinical trial at St. James Hospital, Leeds. The trial tests the drug TG6002 on colorectal cancer patients with inoperable liver metastasis. At the Leeds trial, the new drug was delivered directly into the…
Details